Electrocardiogram characteristics of methadone and buprenorphine maintained subjects

Journal of Addictive Diseases

Volumn 27, Issue 3, 2008, Pages 31-35

  Athanasos, Peter ^a   Farquharson, Aaron L ^a   Compton, Peggy ^b   Psaltis, Peter ^a   Hay, Justin ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Electrocardiogram; Elongated QTc; Methadone

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; QT PROLONGATION; SUBSTITUTION THERAPY; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; LONG QT SYNDROME; LONG TERM CARE; MIDDLE AGED; RISK FACTOR;

ADULT; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; LONG-TERM CARE; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; RISK FACTORS;

EID: 58149144783     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880802122596     Document Type: Article

References (15)

1. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965; 193(8):80-4.
2. Brown R et al. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J. 2004;80(949):654-9.
3. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29(3):297-326.
4. Krantz MJ et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137(6):501-4.
5. Martell BA et al. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95(7):915-8.
6. Hlaing T et al. ECG repolarization waves: their genesis and clinical implications. Ann Noninvasive Electrocardiol. 2005;10(2):211-23.
7. Bazett H. An analysis of the time-relations of electrocardiogram. Heart. 1920;7:353-370.
8. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72(6):23B-25B.
9. Moss A et al. ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Ann Noninvasive Electrocardiol. 2001;6:333-41.
10. European Agency for the Evaluation of Medicinal Products. EMEA public statement to suspend the marketing authorization for Orlaam (levacetylmethadol) in the European Union. London, UK: 2001.
11. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. Pain. 2003;105(3):499-506.
12. Krantz MJ, Kutinsky IB, Robertson AD, Mehlet PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 2003;23(6):802-5.
13. Krantz MJ, Mehler PS. Synthetic opioids and QT prolongation. Arch Intern Med. 2003;163(13):1615; author reply 1615.
14. Lipski J, Stimmel B, Donoso E. The effect of heroin and multiple drug abuse on the electrocardiogram. Am Heart J. 1973;86(5):663-8.
15. Johnson RE et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290-7.